Schellenberg Wittmer advised Santhera Pharmaceuticals regarding an exclusive license agreement for the Greater China Region with Sperogenix Therapeutics, a China-based company specializing in orphan diseases. Under this agreement, Sperogenix will in-license the drug candidate Vamorolone for Duchenne muscular dystrophy and other rare disease indications for a total consideration of up to USD 124 million, including a double-digit upfront cash compensation and DMD-related US-regulatory milestone payments amounting to a combined USD 20 million, as well as further double-digit royalties on net sales.